CL2023001665A1 - Moléculas de unión a gucy2c y sus usos - Google Patents
Moléculas de unión a gucy2c y sus usosInfo
- Publication number
- CL2023001665A1 CL2023001665A1 CL2023001665A CL2023001665A CL2023001665A1 CL 2023001665 A1 CL2023001665 A1 CL 2023001665A1 CL 2023001665 A CL2023001665 A CL 2023001665A CL 2023001665 A CL2023001665 A CL 2023001665A CL 2023001665 A1 CL2023001665 A1 CL 2023001665A1
- Authority
- CL
- Chile
- Prior art keywords
- gucy2c
- binding molecules
- chimeric antigen
- antigen receptors
- lymphocytes
- Prior art date
Links
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 102100022662 Guanylyl cyclase C Human genes 0.000 abstract 1
- 101000899808 Homo sapiens Guanylyl cyclase C Proteins 0.000 abstract 1
- 108010003723 Single-Domain Antibodies Proteins 0.000 abstract 1
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 239000012642 immune effector Substances 0.000 abstract 1
- 229940121354 immunomodulator Drugs 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/50—Colon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001154—Enzymes
- A61K39/001164—GTPases, e.g. Ras or Rho
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464454—Enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464454—Enzymes
- A61K39/464464—GTPases, e.g. Ras or Rho
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70517—CD8
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y406/00—Phosphorus-oxygen lyases (4.6)
- C12Y406/01—Phosphorus-oxygen lyases (4.6.1)
- C12Y406/01002—Guanylate cyclase (4.6.1.2)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Cell Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- Mycology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Se proporciona anticuerpos de un solo dominio que se unen a GUCY2C y receptores de antígenos quiméricos que los comprenden. Además se proporcionan células efectoras inmunitarias modificadas (tales como linfocitos T) que comprenden los receptores de antígenos quiméricos. También se proporcionan composiciones farmacéuticas, kits y métodos para tratar una enfermedad o trastorno.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2020137164 | 2020-12-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2023001665A1 true CL2023001665A1 (es) | 2024-01-12 |
Family
ID=82060074
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2023001665A CL2023001665A1 (es) | 2020-12-17 | 2023-06-08 | Moléculas de unión a gucy2c y sus usos |
Country Status (15)
Country | Link |
---|---|
US (1) | US20240059794A1 (es) |
EP (1) | EP4263615A1 (es) |
JP (1) | JP2023554467A (es) |
KR (1) | KR20230131183A (es) |
CN (2) | CN118146381A (es) |
AU (1) | AU2021404641A1 (es) |
BR (1) | BR112023011658A2 (es) |
CA (1) | CA3205007A1 (es) |
CL (1) | CL2023001665A1 (es) |
CO (1) | CO2023009279A2 (es) |
CR (1) | CR20230245A (es) |
EC (1) | ECSP23053774A (es) |
IL (1) | IL303610A (es) |
MX (1) | MX2023006969A (es) |
WO (1) | WO2022127871A1 (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2024027815A1 (zh) * | 2022-08-05 | 2024-02-08 | 江苏恒瑞医药股份有限公司 | 特异性结合gucy2c和cd3的抗原结合分子及其医药用途 |
CN115894697B (zh) * | 2022-12-09 | 2023-08-29 | 华道(上海)生物医药有限公司 | 一种抗鸟苷酸环化酶2c的纳米抗体及其应用 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9156915B2 (en) * | 2012-04-26 | 2015-10-13 | Thomas Jefferson University | Anti-GCC antibody molecules |
UA117910C2 (uk) * | 2012-04-27 | 2018-10-25 | Мілленніум Фармасьютікалз, Інк. | Молекула анти-gcc антитіла і її використання для тестування на чутливість до gcc-націленої терапії |
US20190202931A1 (en) * | 2018-01-04 | 2019-07-04 | Lumosa Therapeutics, Co., Ltd. | Single-domain antibody-cytosine deaminase fusion proteins |
KR102584675B1 (ko) * | 2018-05-23 | 2023-10-05 | 화이자 인코포레이티드 | GUCY2c에 특이적인 항체 및 이의 용도 |
-
2021
- 2021-12-16 EP EP21905797.3A patent/EP4263615A1/en active Pending
- 2021-12-16 BR BR112023011658A patent/BR112023011658A2/pt unknown
- 2021-12-16 CA CA3205007A patent/CA3205007A1/en active Pending
- 2021-12-16 CN CN202311602780.2A patent/CN118146381A/zh active Pending
- 2021-12-16 KR KR1020237020647A patent/KR20230131183A/ko unknown
- 2021-12-16 MX MX2023006969A patent/MX2023006969A/es unknown
- 2021-12-16 WO PCT/CN2021/138845 patent/WO2022127871A1/en active Application Filing
- 2021-12-16 US US18/265,779 patent/US20240059794A1/en active Pending
- 2021-12-16 JP JP2023537253A patent/JP2023554467A/ja active Pending
- 2021-12-16 CR CR20230245A patent/CR20230245A/es unknown
- 2021-12-16 CN CN202180093966.2A patent/CN116917329A/zh active Pending
- 2021-12-16 IL IL303610A patent/IL303610A/en unknown
- 2021-12-16 AU AU2021404641A patent/AU2021404641A1/en active Pending
-
2023
- 2023-06-08 CL CL2023001665A patent/CL2023001665A1/es unknown
- 2023-07-13 CO CONC2023/0009279A patent/CO2023009279A2/es unknown
- 2023-07-17 EC ECSENADI202353774A patent/ECSP23053774A/es unknown
Also Published As
Publication number | Publication date |
---|---|
JP2023554467A (ja) | 2023-12-27 |
MX2023006969A (es) | 2023-08-25 |
ECSP23053774A (es) | 2023-09-29 |
CN116917329A (zh) | 2023-10-20 |
CA3205007A1 (en) | 2022-06-23 |
CR20230245A (es) | 2023-09-01 |
AU2021404641A1 (en) | 2023-06-29 |
KR20230131183A (ko) | 2023-09-12 |
CO2023009279A2 (es) | 2023-07-21 |
EP4263615A1 (en) | 2023-10-25 |
WO2022127871A1 (en) | 2022-06-23 |
IL303610A (en) | 2023-08-01 |
BR112023011658A2 (pt) | 2023-10-17 |
US20240059794A1 (en) | 2024-02-22 |
CN118146381A (zh) | 2024-06-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2023001665A1 (es) | Moléculas de unión a gucy2c y sus usos | |
BR112021016984A2 (pt) | Receptores de antígeno quimérico direcionados a dll3 e agentes de ligação | |
CL2019000326A1 (es) | Receptores de antígenos quiméricos dirigidos a bcma y métodos de uso de estos | |
CO2017008462A2 (es) | Anticuerpos anti-cd3, anticuerpos anti-cd123 y anticuerpos biespecíficos que se unen específicamente a cd3 y/o cd123 | |
PE20241349A1 (es) | Anticuerpos de union a cd3 | |
AR069290A1 (es) | Anticuerpos monoclonales que se unen al hgm -csf (factor estimulante de la colonia de granulocitos-macrofagos) y las composiciones medicas que los comprenden | |
BR112022014771A2 (pt) | Anticorpo anti-receptor de transferrina (tfr) e usos do mesmo | |
CL2012002329A1 (es) | Molecula de anticuerpo quimerico que se une a cd37 humano; molecula de adn que codifica la cadena pesada y la cadena liviana de las regiones variables del anticuerpo; vector de expresion y celula huesped que comprende dichos adn; composicion farmaceutica que comprende los anticuerpos; uso de la composicion en la supresion de celulas b (divi. sol. 2349-08) | |
BR112019002168A2 (pt) | anticorpos trivalentes bispecíficos ligantes a claudina6 ou claudina18.2 e cd3 para o tratamento de doenças cancerígenas que expressam claudina | |
BR112019011450A2 (pt) | células naturais killer modificadas e uso das mesmas | |
NI200900022A (es) | Anticuerpo especifico de prlr y usos del mismo | |
BR112018001374A2 (pt) | construtos de anticorpo biespecíficos que se ligam a egfrviii e cd3 | |
AR070453A1 (es) | Anticuerpos dirigidos a angiopoyetina -1 y angiopoyetina-2 y usos de los mismos | |
EA201691925A1 (ru) | Биспецифические антитела, которые связываются с cd38 и cd3 | |
PE20141521A1 (es) | Moleculas biespecificas de union a antigeno activadoras de celulas t | |
CO2020013089A2 (es) | Anticuerpos contra mica y/o micb y sus usos | |
CO2019003759A2 (es) | Anticuerpos que se unen a la proteína de envoltura del virus zika y usos de los mismos | |
AR119746A1 (es) | Anticuerpos multiespecíficos de cadena pesada que se unen a cd22 y cd3 | |
CL2022003004A1 (es) | Agentes de unión a ilt y métodos para su uso | |
BR112021019411A2 (pt) | Métodos para a produção de células car-nk e uso das mesmas | |
CO2022008272A2 (es) | Agentes de unión a ilt3 y métodos de uso de los mismos | |
DOP2023000158A (es) | Anticuerpo triespecífico dirigido a bcma, gprc5d, y cd3 | |
CL2022000096A1 (es) | Anticuerpos anti-tigit y aplicación de los mismos | |
CO2023000808A2 (es) | Unión de anticuerpos multiespecíficos a bcma | |
BR112022012524A2 (pt) | Porção química de ligação que se liga especificamente a claudin18.2, polinucleotídeo, vetor, célula hospedeira, receptor de antígeno quimérico (car ), célula imune geneticamente modificada, composição farmacêutica, método de tratamento de um tumor ou câncer que expressa claudin18.2 |